High Tech Pharm하이텍팜
106190 · KOSDAQ · ₩106190 · 하이텍팜
- Market cap
- ₩95B
- Enterprise value
- ₩93B
- P/E
- 8.0×
- P/B
- 0.7×
- Dividend yield
- 0.0%
- ROE
- 8.9%
- Net margin
- 17.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−64.1% from the high
₩8,400Today: ₩8,690 – ₩9,010₩25,000
Returns
- 1W−4.1%
- 1M−10.2%
- 3M−9.8%
- 6M−53.9%
- YTD−25.3%
- 1Y−32.8%
- Volume today
- 23,878
- 1.2× the 20-day average
- Traded today
- ₩212M
- Listed shares
- 10,633,173
- EPS (12 months)
- ₩1,122
- Earnings yield 12.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 47 of 100 (50 is a normal day for this stock).
- MomentumWeak-9.1% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
High Tech Pharm stock overview
High Tech Pharm (하이텍팜, KRX: 106190) is listed on KOSDAQ, in the Biotech & Pharma sector. Hightech Pharmaceutical is a Korean active pharmaceutical ingredient (API) maker founded in 1998 that specializes in injectable antibiotic ingredients, mainly carbapenem-class antibiotics such as imipenem and ertapenem. Its shares closed at ₩8,980 on Oct 28, 2026, up 1.13% on the day, giving it a market value of ₩95B.
Key facts
- Market cap
- ₩95B
- Sector
- Biotech & Pharma
- Latest price change
- +1.13%
- As of
- Oct 28, 2026
- Main business
- Hightech Pharmaceutical is a Korean active pharmaceutical ingredient (API) maker founded in 1998 that specializes in injectable antibiotic ingredients, mainly carbapenem-class antibiotics such as imipenem and ertapenem.
Quick answers about High Tech Pharm
- What does High Tech Pharm do?
- Hightech Pharmaceutical is a Korean active pharmaceutical ingredient (API) maker founded in 1998 that specializes in injectable antibiotic ingredients, mainly carbapenem-class antibiotics such as imipenem and ertapenem. Its products are sold almost entirely abroad, with about 87% of sales to Europe and about 13% to Asia, and the company is working to expand sales in regulated markets such as Asia and North America. Its production is based in Chungju, Korea.
- What is the market cap of High Tech Pharm?
- The market capitalisation of High Tech Pharm was ₩95B at the close on Oct 28, 2026.
- Who are the largest shareholders of High Tech Pharm?
- According to the latest official filings, the largest reported holders are ACSDOBFARS.P.A (45.14%, as of Aug 12, 2026); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.06%, as of Jul 31, 2026); Kang Sin-jun (0.06%, as of Aug 12, 2026).
- When is the next earnings report from High Tech Pharm?
- Korean companies rarely announce results dates in advance. Based on when High Tech Pharm filed the same report in past years, its next 3q results is expected between Nov 12, 2026 and Nov 14, 2026.
Company profile
Hightech Pharmaceutical is a Korean active pharmaceutical ingredient (API) maker founded in 1998 that specializes in injectable antibiotic ingredients, mainly carbapenem-class antibiotics such as imipenem and ertapenem. Its products are sold almost entirely abroad, with about 87% of sales to Europe and about 13% to Asia, and the company is working to expand sales in regulated markets such as Asia and North America. Its production is based in Chungju, Korea.
Written by AI from the company's latest annual report.
- Korean name
- 하이텍팜
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 차현준
- Founded
- Sep 1998
- Listed
- Jul 2010
- Listed shares
- 10,633,173
- Fiscal year ends
- Month 12
- Website
- www.htpharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Amended: Half-year report (Jun 2026)Sep 29, 2026
- Amended: Half-year report (Jun 2026)Aug 14, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportAug 12, 2026
- Insider shareholding reportAug 12, 2026
Titles in Korean until English translations are added.
Also known as: High Tech Pharm / 하이텍팜 / 106190 / KRX:106190
Source: KRX statistical information